无症状颈动脉狭窄血运重建结局:卒中中心分析
该回顾性队列研究纳入2015–2024年单中心275例无症状颈动脉狭窄患者共293次干预,比较CEA、TCAR与TFCAS的30天及中期结局。三组30天复合终点无差异,TFCAS再狭窄率显著更高。SEVSG区域数据同样显示TFCAS中期复合终点和再狭窄率更高。
要点
- 无症状颈动脉狭窄中CEA、TCAR与TFCAS的30天卒中/死亡复合结局无显著差异。
- TFCAS再狭窄率显著高于CEA和TCAR,区域数据中亦如此。
- 闭孔支架使用与再狭窄风险独立相关(HR 6.48)。
核心结论
- 单中心数据显示无症状颈动脉狭窄患者接受CEA、TFCAS或TCAR的结局相当。
- TFCAS在单中心队列和区域数据集中均与更高的再狭窄率相关。
- 结果提示需个体化选择血运重建方式。
研究设计与样本
- 回顾性队列研究,纳入2015–2024年单卒中中心无症状颈动脉狭窄血运重建患者。
- 共275例患者、293次颈动脉干预:CEA 158次(53.9%)、TCAR 68次(23.2%)、TFCAS 67次(22.9%)。
- 另用SEVSG区域数据库比较CEA与TFCAS结局。
主要发现
- 30天复合终点(同侧卒中/TIA/MI/死亡):TFCAS 3.0%、CEA 1.9%、TCAR 0.0%(P=0.34)。
- 中期随访1.6±1.5年复合终点:CEA 15.8%、TFCAS 13.4%、TCAR 25.5%(P=0.15)。
- 再狭窄率:CEA 0.0%、TFCAS 7.5%、TCAR 2.9%(P<0.01);再干预率:CEA 0.0%、TFCAS 6.0%、TCAR 0.0%(P<0.01)。
- 闭孔支架与再狭窄风险独立相关(HR 6.48,95%CI 1.14–36.76,P=0.02)。
- SEVSG数据:30天复合终点CEA 2.3% vs TFCAS 1.3%(P=0.45);中期复合终点CEA 7.8% vs TFCAS 11.1%(P<0.01);再狭窄率CEA 0.3% vs TFCAS 13.8%(P<0.01)。
临床怎么用
- 无症状颈动脉狭窄血运重建方式选择应个体化,综合考虑再狭窄风险。
- TFCAS术后需加强再狭窄监测,闭孔支架使用或需更密切随访。
局限性
- 单中心回顾性设计,样本量有限。
- 区域数据库死亡原因多为未知,可能影响结局判定。
- 中期随访时间较短(1.6±1.5年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: High-grade asymptomatic carotid artery stenosis is a well-established risk factor for cerebrovascular events. While carotid endarterectomy (CEA) remains the standard of care, transfemoral carotid artery stenting (TFCAS) and transcarotid artery revascularization (TCAR) have emerged as less invasive alternatives. METHODS: This retrospective cohort study included patients with asymptomatic carotid stenosis who underwent revascularization at a stroke center between 2015 and 2024. Primary and secondary outcomes included rates of ipsilateral stroke, transient ischemic attack (TIA), myocardial infarction (MI), and death at 30 days and on mid-term follow-up. Restenosis and reintervention rates were also evaluated. In addition, the outcomes of CEA and TFCAS were compared using data from the Southeastern Vascular Study Group (SEVSG) regional database. RESULTS: A total of 275 patients underwent 293 carotid artery interventions, including 158 (53.9%) CEA, 68 (23.2%) TCAR, and 67 (22.9%) TFCAS. There were no differences in baseline characteristics except for a significantly higher proportion of male patients in the TCAR group (CEA: 61.4%, TFCAS: 56.7%, TCAR: 77.9%, P = 0.02) and lower body mass index in the CEA group (CEA: 27.7 ± 4.6, TFCAS: 29.7 ± 5.6, TCAR: 29.4 ± 5.5, P < 0.01). The composite outcome of ipsilateral stroke/TIA/MI/death within 30-days following the procedure was not different among the groups (TFCAS: 3.0%, CEA: 1.9%, TCAR: 0.0%, P = 0.34), with no significant differences in death rates (CEA: 1.9%, TFCAS: 1.5%, TCAR: 0.0%, P = 0.67) or ipsilateral stroke rates (CEA: 0.0%, TFCAS: 1.5%, TCAR: 0.0%, P = 0.23). No MI or TIA events were observed. At mid-term follow-up of 1.6 ± 1.5 years, the composite outcome was also similar (CEA: 15.8%, TFCAS: 13.4%, TCAR: 25.5%, P = 0.15), with no significant differences in ipsilateral stroke rates (CEA: 1.3%, TFCAS: 4.5%, TCAR: 0.0%, P = 0.11), TIA rates (CEA: 0.0%, TFCAS: 3.0%, TCAR: 0.0%, P = 0.05), MI rates (CEA: 1.3%, TFCAS: 1.5%, TCAR: 4.4%, P = 0.3), or death rates (CEA: 13.3%, TFCAS: 6.0%, TCAR: 19.1%; P = 0.07). The TFCAS group had a significantly higher rate of restenosis (CEA: 0.0%, TFCAS: 7.5%, TCAR: 2.9%, P < 0.01) and reintervention compared to the CEA and TCAR groups (CEA: 0.0%, TFCAS: 6.0%, TCAR: 0.0%, P < 0.01). On multivariable Cox regression analysis, the use of closed-cell stents was independently associated with a higher risk of restenosis (hazard ratio 6.48, 95% confidence interval 1.14-36.76, P = 0.02). From the SEVSG regional analysis, 30-day term outcomes demonstrated no significant differences in ipsilateral stroke (CEA: 0.5%, TFCAS: 0.4%, P = 0.87), TIA (CEA: 0.2%, TFCAS: 0.0%, P = 0.49), death rates (CEA: 1.6%, TFCAS: 0.9%, P = 0.43), or composite outcomes (CEA: 2.3%, TFCAS: 1.3%, P = 0.45), while mid-term outcomes revealed higher composite rates (CEA: 7.8%, TFCAS: 11.1%, P < 0.01) and death rates in the TFCAS group (CEA: 4.2%, TFCAS: 8.2%, P < 0.01). Most deaths were of unknown causes within our regional dataset (CEA: 1.75%, TFCAS: 4.5%), followed by non-carotid-related causes (CEA: 2.4%, TFCAS: 3.6%). Restenosis rates were higher in the TFCAS group compared to the CEA group (CEA: 0.3%, TFCAS: 13.8%, P < 0.01). Reintervention rates were higher, but not significant, in the TFCAS group (CEA: 1.0%, TFCAS: 1.8%, P = 0.05). CONCLUSION: Our stroke center's results demonstrate comparable outcomes following CEA, TFCAS, and TCAR in the asymptomatic carotid artery stenosis patient population. TFCAS was associated with higher restenosis rates in both in our cohort and the regional dataset. These findings emphasize the need for an individualized approach when considering carotid artery revascularization in this patient population.
引用
- Esquetini-Vernon C, Meschia JF, Rajab M, et al. Outcomes of Carotid Artery Revascularization in Asymptomatic Carotid Artery Stenosis: A Stroke Center Analysis. Ann Vasc Surg. 2025. PMID: 41237977. doi:10.1016/j.avsg.2025.11.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。